GXI: Probe, Radiofrequency Lesion

Product code GXI, “Probe, Radiofrequency Lesion” in FDA's classification database, is a Class II device type under 21 CFR 882.4725 (radiofrequency lesion probe), reviewed by FDA's Neurology panel. FDA's 510(k) database lists 66 clearances under GXI, 28 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
GXI
Regulation
21 CFR 882.4725
Class
II
Panel
Neurology
Clearances
66
Most recent
Apr 16, 2026
Median review, last 2 years
189 days
Third-party review
Eligible
Implant
No

What it covers

A radiofrequency lesion probe is a device connected to a radiofrequency (RF) lesion generator to deliver the RF energy to the site within the nervous system where a lesion is desired.

The identification in 21 CFR 882.4725, radiofrequency lesion probe. FDA gives GXI no definition of its own, so the regulation’s describes it.

Recent clearances

510(k)DeviceApplicantDecisionType
K253907Disposable Radiofrequency CannulaABBOTT MEDICALApr 16, 2026Traditional
K251802STAR RF Ablation SystemMerit Medical Systems, Inc.Feb 13, 2026Traditional
K251243OneRF Trigeminal Nerve Radiofrequency ProbesNeuroone Medical Technologies Corp.Aug 15, 2025Traditional
K242841Disposable RF Electrode (RFDE-5/RFDE-10/RFDE-15/RFDE-20)ABBOTT MEDICALMay 27, 2025Traditional
K250213OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Single Kit); OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Dual Kit)Stryker InstrumentsMay 15, 2025Traditional
K241367RF CannulaShanghai Samedical & Plastic Instruments Co., Ltd.Jan 23, 2025Traditional
K222281Intracept Intraosseous Nerve Ablation SystemRelievant Medsystems, Inc.Oct 26, 2022Traditional
K213836Intracept Intraosseous Nerve Ablation SystemRelievant Medsystems, Inc.Mar 11, 2022Traditional
K203066COOLIEF Cooled Radiofrequency Kit AdvancedAvanos Medical, Inc.Dec 22, 2020Traditional
K190259Vesta RF CannulaBiomericsFeb 7, 2020Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 66 with a free account)

Clearances by year

28 GXI 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)2189
20254183
2022291
20203255
2019363
20181214
20173125
20163240
20151167
20141200
20131170
2012195
2011364

Who submits

15 applicants cleared a GXI device since 2011. 68% of the clearances went to applicants in United States, then Canada (18%) and China (14%). By type: Traditional 86% and Special 14%. 5 went through a third-party review organization.

ApplicantClearances since 2011
Diros Technology, Inc.5
Relievant Medsystems4
Lccs Products Limited3
ABBOTT MEDICAL2
Biomerics2
Halyard Health, Inc.2
Relievant Medsystems, Inc.2
Avanos Medical, Inc.1

How FDA classifies it

Class II (performance standards).

From 21 CFR 882.4725.

Standards

21 CFR 882.4725 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent GXI clearances declared.

Ask about GXI

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about GXI

What is FDA product code GXI?

Product code GXI, “Probe, Radiofrequency Lesion” in FDA's classification database, is a Class II device type under 21 CFR 882.4725 (radiofrequency lesion probe), reviewed by FDA's Neurology panel. FDA's 510(k) database lists 66 clearances under GXI, 28 of them since 2011.

How many 510(k) clearances are there under GXI?

FDA’s 510(k) database listed 66 clearances under GXI as of Oct 29, 2026, 28 of them decided since 2011; the most recent decision was Apr 16, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a GXI 510(k)?

For the 6 GXI clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 189 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most GXI clearances?

Since 2011: Diros Technology, Inc. (5), Relievant Medsystems (4), Lccs Products Limited (3), ABBOTT MEDICAL (2) and Biomerics (2). 15 applicants have cleared a GXI device in that time.

Sources

  1. FDA product classification: GXI · Product Classification database
  2. 21 CFR 882.4725: Radiofrequency lesion probe · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for GXI · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow GXIGet an email when FDA clears, recalls or publishes guidance for GXI devices.

Know what FDA already cleared.